Tempus AI reported Q1 revenue of $348.1 million, up 36% year over year, and raised full-year guidance on the back of stronger diagnostics volume. The company highlighted minimal residual disease (MRD) test volume rising about sixfold to roughly 6,500 tests. Tempus also disclosed partnerships intended to deepen biomarker discovery and development, including a multi-year collaboration with Merck using its multimodal data and Lens analytical platform. The company expanded its collaboration with Gilead to provide enterprise-wide access to Lens and datasets supporting oncology pipeline efforts. While Tempus’ net loss widened to $125.9 million, it exited the quarter with $521.2 million in cash, indicating continued runway as it scales algorithm deployment and oncology-focused testing operations.